Published in Trop Med Int Health on February 01, 2006
Performance of an ELISA and indirect immunofluorescence assay in serological diagnosis of zoonotic cutaneous leishmaniasis in iran. Interdiscip Perspect Infect Dis (2014) 0.79
Leishmaniases diagnosis: an update on the use of immunological and molecular tools. Cell Biosci (2015) 0.79
Detection of anti-leishmania (Leishmania) chagasi immunoglobulin G by flow cytometry for cure assessment following chemotherapeutic treatment of American visceral leishmaniasis. Clin Vaccine Immunol (2007) 0.78
Utility of Western Blot Analysis for the Diagnosis of Cutaneous Leishmaniasis. Iran J Parasitol (2016) 0.75
Detection of IgG Anti-Leishmania Antigen by Flow Cytometry as a Diagnostic Test for Cutaneous Leishmaniasis. PLoS One (2016) 0.75
Flow cytometric determination of cellular sources and frequencies of key cytokine-producing lymphocytes directed against recombinant LACK and soluble Leishmania antigen in human cutaneous leishmaniasis. Infect Immun (2001) 1.90
Evidence that development of severe cardiomyopathy in human Chagas' disease is due to a Th1-specific immune response. Infect Immun (2003) 1.81
Transmission of tuberculosis to close contacts of patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med (1996) 1.57
Simple form of clinical sample preservation and Leishmania DNA extraction from human lesions for diagnosis of American cutaneous leishmaniasis via polymerase chain reaction. Am J Trop Med Hyg (2001) 1.53
Cellular responses and cytokine production in post-treatment hookworm patients from an endemic area in Brazil. Clin Exp Immunol (2004) 1.49
Acetylcholine receptors and neuronal nitric oxide synthase distribution at the neuromuscular junction of regenerated muscle fibers. Muscle Nerve (2001) 1.40
PCR detection of Trypanosoma cruzi DNA in oesophageal tissues of patients with chronic digestive Chagas' disease. Lancet (1996) 1.26
A combination of benznidazole and ketoconazole enhances efficacy of chemotherapy of experimental Chagas' disease. J Antimicrob Chemother (2000) 1.23
Impact of canine control on the epidemiology of canine and human visceral leishmaniasis in Brazil. Am J Trop Med Hyg (2001) 1.16
Activated T and B lymphocytes in peripheral blood of patients with Chagas' disease. Int Immunol (1994) 1.16
Controlled field trials of a vaccine against New World cutaneous leishmaniasis. Int J Epidemiol (1986) 1.15
Impaired regeneration of dystrophin-deficient muscle fibers is caused by exhaustion of myogenic cells. Braz J Med Biol Res (2002) 1.15
Chagasic patients lack CD28 expression on many of their circulating T lymphocytes. Scand J Immunol (1996) 1.14
IFN-gamma in human Chagas' disease: protection or pathology? Braz J Med Biol Res (1998) 1.13
Characterization of human T lymphocyte-mediated immune responses induced by a vaccine against American tegumentary leishmaniasis. Am J Trop Med Hyg (1995) 1.11
Analysis of the cytokine profile in spleen cells from dogs naturally infected by Leishmania chagasi. Vet Immunol Immunopathol (2006) 1.10
Foxp3+CD25(high) CD4+ regulatory T cells from indeterminate patients with Chagas disease can suppress the effector cells and cytokines and reveal altered correlations with disease severity. Immunobiology (2012) 1.09
Evaluation of the stability and immunogenicity of autoclaved and nonautoclaved preparations of a vaccine against American tegumentary leishmaniasis. Vaccine (1999) 1.09
Are increased frequency of macrophage-like and natural killer (NK) cells, together with high levels of NKT and CD4+CD25high T cells balancing activated CD8+ T cells, the key to control Chagas' disease morbidity? Clin Exp Immunol (2006) 1.08
Leishmania identification by PCR of Giemsa-stained lesion imprint slides stored for up to 36 years. Clin Microbiol Infect (2006) 1.07
Stage-specific immune responses in human Necator americanus infection. Parasite Immunol (2007) 1.05
Cytokines as determinants of resistance and pathology in human Schistosoma mansoni infection. Braz J Med Biol Res (1998) 1.05
Cytokine production associated with periportal fibrosis during chronic schistosomiasis mansoni in humans. Infect Immun (2006) 1.05
Activation/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: is this the key to prevent severe adverse reactions following immunization? Clin Exp Immunol (2007) 1.05
Strategy to assess the overall cytokine profile of circulating leukocytes and its association with distinct clinical forms of human Chagas disease. Scand J Immunol (2008) 1.04
Chagasic patients with indeterminate clinical form of the disease have high frequencies of circulating CD3+CD16-CD56+ natural killer T cells and CD4+CD25High regulatory T lymphocytes. Scand J Immunol (2005) 1.03
Anti-Trypanosoma cruzi immunoglobulin G1 can be a useful tool for diagnosis and prognosis of human Chagas' disease. Clin Diagn Lab Immunol (2001) 1.02
Immune response in human visceral leishmaniasis: analysis of the correlation between innate immunity cytokine profile and disease outcome. Scand J Immunol (2005) 1.00
Relationship between canine visceral leishmaniosis and the Leishmania (Leishmania) chagasi burden in dermal inflammatory foci. J Comp Pathol (2006) 0.99
A field trial of a vaccine against American dermal leishmaniasis. Trans R Soc Trop Med Hyg (1979) 0.99
Immunochemotherapy in American cutaneous leishmaniasis: immunological aspects before and after treatment. Mem Inst Oswaldo Cruz (2001) 0.99
Phenotypic features of circulating leucocytes as immunological markers for clinical status and bone marrow parasite density in dogs naturally infected by Leishmania chagasi. Clin Exp Immunol (2006) 0.99
Leishmanicidal activity of benzophenones and extracts from Garcinia brasiliensis Mart. fruits. Phytomedicine (2009) 0.98
The role of the immune response on the development of severe clinical forms of human Chagas disease. Mem Inst Oswaldo Cruz (1999) 0.98
Vaccine for prophylaxis and immunotherapy, Brazil. Clin Dermatol (1997) 0.97
Human Schistosomiasis mansoni: IL-10 modulates the in vitro granuloma formation. Parasite Immunol (1998) 0.97
Vaccination of humans against cutaneous leishmaniasis: cellular and humoral immune responses. Infect Immun (1990) 0.95
Diagnosis of canine leishmaniasis in the endemic area of Belo Horizonte, Minas Gerais, Brazil by parasite, antibody and DNA detection assays. Vet Res Commun (2006) 0.95
American cutaneous leishmaniasis in Southeast Brazil: space-time clustering. Int J Epidemiol (1999) 0.95
Atypical mucocutaneous leishmaniasis caused by Leishmania braziliensis in an acquired immunodeficiency syndrome patient: T-cell responses and remission of lesions associated with antigen immunotherapy. Mem Inst Oswaldo Cruz (1999) 0.95
Electrocardiographic characteristics in a population with high rates of seropositivity for Trypanosoma cruzi infection. Am J Trop Med Hyg (2007) 0.94
Benznidazole treatment during early-indeterminate Chagas' disease shifted the cytokine expression by innate and adaptive immunity cells toward a type 1-modulated immune profile. Scand J Immunol (2006) 0.92
[Standardization of the Montenegro antigen]. Rev Inst Med Trop Sao Paulo (1978) 0.92
Humoral and cellular immune responses in dogs with inapparent natural Leishmania infantum infection. Vet J (2011) 0.92
Phenotypic features of peripheral blood leucocytes during early stages of human infection with Trypanosoma cruzi. Scand J Immunol (2003) 0.91
Analysis of the effects of treatment of human Schistosoma mansoni infection on the immune response of patients from endemic areas. Acta Trop (2000) 0.91
Histopathology and immunocytochemical study of type 3 and type 4 complement receptors in the liver and spleen of dogs naturally and experimentally infected with Leishmania (Leishmania) chagasi. Rev Inst Med Trop Sao Paulo (1997) 0.90
Follow-up of experimental chronic Chagas' disease in dogs: use of polymerase chain reaction (PCR) compared with parasitological and serological methods. Acta Trop (2002) 0.90
Montenegro skin test--evaluation of the composition and stability of the antigen preparation. Mem Inst Oswaldo Cruz (1997) 0.89
HLA class II alleles and chronic hepatitis C virus infection. Scand J Immunol (2011) 0.89
Epidemiology of dermal leishmaniasis in the Rio Doce Valley, State of Minas Gerais, Brazil. Ann Trop Med Parasitol (1979) 0.88
Persistence of PCR-positive tissue in benznidazole-treated mice with negative blood parasitological and serological tests in dual infections with Trypanosoma cruzi stocks from different genotypes. J Antimicrob Chemother (2008) 0.87
A randomized double-blind placebo-controlled trial to evaluate the immunogenicity of a candidate vaccine against American tegumentary leishmaniasis. Acta Trop (2001) 0.87
Evaluation of the influence of tissue parasite density on hematological and phenotypic cellular parameters of circulating leukocytes and splenocytes during ongoing canine visceral leishmaniasis. Parasitol Res (2008) 0.87
[Optical and electron microscopic study of the kidney of dogs naturally and experimentally infected with Leishmania (Leishmania) chagasi]. Rev Inst Med Trop Sao Paulo (1990) 0.86
Hepatitis C virus infection among Brazilian hemophiliacs: a virological, clinical and epidemiological study. Braz J Med Biol Res (2002) 0.86
In vitro activity of hypnophilin from Lentinus strigosus: a potential prototype for Chagas disease and leishmaniasis chemotherapy. Braz J Med Biol Res (2010) 0.86
An experimental vaccine against American dermal leishmaniasis: experience in the State of Espírito Santo, Brazil. Ann Trop Med Parasitol (1985) 0.86
Effect of chemotherapy with praziquantel on the production of cytokines and morbidity associated with schistosomiasis mansoni. Antimicrob Agents Chemother (2008) 0.86
IL-10 produced by CD4+ and CD8+ T cells emerge as a putative immunoregulatory mechanism to counterbalance the monocyte-derived TNF-alpha and guarantee asymptomatic clinical status during chronic HTLV-I infection. Clin Exp Immunol (2007) 0.85
Widespread heteroplasmy in schistosomes makes an mtVNTR marker "nearsighted". J Hered (2001) 0.85
Posttherapeutic cure criteria in Chagas' disease: conventional serology followed by supplementary serological, parasitological, and molecular tests. Clin Vaccine Immunol (2012) 0.85
Phenotypic study of peripheral blood leucocytes in HTLV-I-infected individuals from Minas Gerais, Brazil. Scand J Immunol (2002) 0.85
Natural killer cell subpopulations in putative resistant individuals and patients with active Mycobacterium tuberculosis infection. Scand J Immunol (2008) 0.85
Comparison of acute physiology and chronic health evaluation II death risk, Child-Pugh, Charlson, and model for end-stage liver disease indexes to predict early mortality after liver transplantation. Transplant Proc (2011) 0.85